Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Claritev’s story has shifted to a more cautious footing, with the top-end fair value ...

DURHAM, N.C., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...

CTEV is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of CTEV shares has increased $1.25 since the market last closed. This is a 9.21 ...

The average one-year price target for Claritev (NYSE:CTEV) has been revised to $90.10 / share. This is an increase of 15.22% from the prior estimate of $78.20 dated November 7, 2025. The price target ...

The average one-year price target for Claritev (NYSE:CTEV) has been revised to $66.10 / share. This is a decrease of 26.64% from the prior estimate of $90.10 dated December 18, 2025. The price target ...

I appreciate everyone dialing in this morning, super excited to host the Claritev team. We've got the whole team here. We've got Travis Dalton, the CEO; Doug Garis, the CFO; and Jerry Hogge, the COO, ...

Claritev Corp. Annual cash flow by MarketWatch. View CTEV net cash flow, operating cash flow, operating expenses and cash dividends.

Sept. 30, 2005 — The U.S. Food and Drug Administration (FDA) has approved a rapid test for the differential diagnosis of influenza A and B that is also capable of detecting avian flu isolates; a ...